Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Wedel

Showing results (151-160 of 161) with videos related to

Pageof 17
Sort By:
Archives of Internal Medicine|October 14, 1996
Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival StudyT R Pedersen, K Berg, T J Cook, et al.
American Journal of Hypertension|August 19, 2000
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For EndpointS E Kjeldsen, B Dahlöf, R B Devereux, et al.
The American Journal of Cardiology|August 3, 2000
Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol loweringT R Pedersen, L Wilhelmsen, O Faergeman, et al.
American Journal of Hypertension|July 1, 1997
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study GroupB Dahlöf, R Devereux, U de Faire, et al.
Circulation|May 12, 1998
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)T R Pedersen, A G Olsson, O Faergeman, et al.
The Journal of Clinical Investigation|June 1, 1983
Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS)I Ringqvist, L D Fisher, M Mock, et al.
Hypertension (Dallas, Tex. : 1979)|December 18, 1998
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in HypertensionB Dahlöf, R B Devereux, S Julius, et al.
Journal of Human Hypertension|April 23, 2004
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE studyH M Reims, S E Kjeldsen, W E Brady, et al.
European Heart Journal|June 6, 2003
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE projectR M Conroy, K Pyörälä, A P Fitzgerald, et al.
JAMA|March 14, 2000
Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study GroupA Hjalmarson, S Goldstein, B Fagerberg, et al.
Pageof 17

Showing results (151-160 of 161) with videos related to

Sort By:
Pageof 17
Archives of Internal Medicine|October 14, 1996
Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival StudyT R Pedersen, K Berg, T J Cook, et al.
American Journal of Hypertension|August 19, 2000
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For EndpointS E Kjeldsen, B Dahlöf, R B Devereux, et al.
The American Journal of Cardiology|August 3, 2000
Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol loweringT R Pedersen, L Wilhelmsen, O Faergeman, et al.
American Journal of Hypertension|July 1, 1997
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study GroupB Dahlöf, R Devereux, U de Faire, et al.
Circulation|May 12, 1998
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)T R Pedersen, A G Olsson, O Faergeman, et al.
The Journal of Clinical Investigation|June 1, 1983
Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS)I Ringqvist, L D Fisher, M Mock, et al.
Hypertension (Dallas, Tex. : 1979)|December 18, 1998
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in HypertensionB Dahlöf, R B Devereux, S Julius, et al.
Journal of Human Hypertension|April 23, 2004
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE studyH M Reims, S E Kjeldsen, W E Brady, et al.
European Heart Journal|June 6, 2003
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE projectR M Conroy, K Pyörälä, A P Fitzgerald, et al.
JAMA|March 14, 2000
Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study GroupA Hjalmarson, S Goldstein, B Fagerberg, et al.
Pageof 17